Browsing Tag
HER2-mutant NSCLC
1 post
Thermo Fisher wins FDA approval for next-generation sequencing companion diagnostic tied to new HER2-mutant NSCLC therapy
Thermo Fisher wins FDA approval for its Oncomine Dx Target Test as a companion diagnostic for Boehringer Ingelheim’s new HER2-mutant NSCLC therapy.